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ABSTRACT: A bio-inspired nanodevice for the selective and sensitive fluorogenic detection of 3,4-
methylenedioxypyrovalerone (MDPV), usually known as Cannibal drug, is reported. The sensing nanodevice is based on 
mesoporous silica nanoparticles (MSNs), loaded with a fluorescent reporter (rhodamine B) and functionalized on their 
external surface with a dopamine derivative (3), which specifically interacts with the recombinant human dopamine 
transporter (DAT), capping the pores. In the presence of MDPV, DAT detaches from the MSNs consequently causing 
rhodamine B release and allowing drug detection. The nanosensor shows a detection limit of 5.2 µM and it is able to detect 
the MDPV drug both in saliva and blood plasma samples.
Over the last years, the unprecedented growth in the 
number of new psychoactive substances (NPS) globally 
available and the expansion of a more dynamic illegal 
market for these drugs is causing a great threat to public 
safety. Regarding last studies published, an estimated 271 
million people worldwide had used psychoactive drugs at 
least once during 2019; roughly 5.5 % of the global 
population.1, 2 Moreover, psychostimulants have reached 
popularity as potent abuse drugs.3 Among NPS, synthetic 
cathinones have arisen as the most widespread class 
designed drugs. This new group of recreational drugs, 
commonly known as “bath salts”, “legal highs”, “plant food” 
or “research chemicals”, acts improving the function of the 
three main monoamine neurotransmitters: i.e. dopamine, 
norepinephrine and serotonin.4, 5 With regard to physical 
forms, cathinones are odourless, white or brownish solids, 
commonly presented in the illegal market as powders or 
fine crystals, and less frequently as tablets or capsules.6, 7 
Main administration routes reported of cathinones are 
insufflation (snorting), oral ingestion (the substance is 
diluted in water or juice drink), and “bombing” (wrapping 
powders in a cigarette paper and next swallowed).8 
Structurally, cathinones are β-ketone derivatives of 
psychoactive phenylalkylamine alkaloids; a naturally 
occurring stimulant in the khat plant (Catha edulis). One of 
the most remarkable constituents of the cathinones family 
is 3,4-methylenedioxypyrovalerone (MDPV). MDPV is 
popularly known as “Cannibal drug”, because, when taken 
in high doses, it spurs users into violent outbreaks of 
aggression, paranoia and panic attacks.9 MDPV differs from 
other synthetic cathinones in the fact that it contains a 
pyrrolidine ring, which gives the drug potent actions as an 
uptake blocker of dopamine and norepinephrine 
transporters. When consumed, MDPV links to the 
dopamine active transporter (DAT), blocking dopamine 
reuptake out of the synaptic cleft. In this way, MDPV leads 
to a rise in the extracellular dopamine levels, causing a 
powerful locomotive enhancement even ten times more 
potent than that produced by cocaine.10-12 Moreover, MDPV 
potentially produces some adverse effects derived from 
long-lasting psychostimulant-type toxidrome, including 
severe agitation, violent behavior, tachycardia, psychosis, 
profuse diaphoresis, paranoia and anxiety, among others. 
Currently reported intoxications involving MDPV13, 14 
stablished that the amount of synthetic cathinones 
consumed per dose ranged from 5 to 250 mg orally which 
produced effects lasting from 1 to 3 h.15
MDPV is commonly detected by different techniques 
such as HPLC-MS,16-19 GC-MS,20-22 HPIMS,23 and 
bioanalytical procedures.24-26 Nevertheless, these methods 
are slow, the samples must be moved to qualified 
laboratories and they usually require the supervision of 
trained personnel. An alternative promising approach to 
these techniques involves the development of chromo-





























































fluorogenic sensors for the rapid, selective and ‘in-situ’ 
detection of MDPV.27 However, as far as we know, no 
chromo-fluorogenic probes have been reported for the 
detection of MDPV so far. In this scenario, the development 
of new strategies to detect and quantify “drugs of abuse” 
like MDPV in a fast, easy, and reliable way is timely and 
urgently required.
Scheme 1. Sensing behavior of solid S2 in the presence of 
MDPV.
From another point of view, the development of hybrid 
organic-inorganic gated materials based on mesoporous 
silica nanoparticles (MSNs) with applications in drug 
delivery,28,29 communication30,31 and detection protocols32-
34 has attracted great attention over the last decade. The 
main advantages provided by MSNs are high specific 
surface area, homogeneous porosity, high load capacity, 
tunable pore size (2-10 nm) and easy functionalization. 
These sensing gated materials allow the controlled release 
of an entrapped cargo in the presence of a target molecule, 
usually triggering the displacement of the gating 
ensemble.35 Moreover, these capped sensing materials also 
show inherent chemical amplification as only few 
molecules of the analyte can induce the delivery of a large 
amount of the entrapped cargo (usually a fluorophore).36
Based on the above, we report herein a gated 
nanodevice for the selective, sensitive fluorogenic sensing 
of MDPV (Scheme 1). The sensor selectively detects MDPV 
at concentrations as low as 5.2 µM and is able to determine 
the presence of MDPV both in saliva and blood plasma. 
EXPERIMENTAL SECTION
Synthesis of mesoporous silica nanoparticles. NaOH 
(2.00 mol L-1, 3.5 mL) was added to a solution of CTABr 
(1.00 g, 2.74 mmol) in deionized H2O (480 mL) at 40 °C. 
The solution temperature was adjusted to 80 °C and then 
TEOS (5.00 mL, 2.57 × 10-2 mol) was added dropwise. The 
mixture was stirred for 2 h to give a white precipitate. The 
solid was isolated by centrifugation and washed with 
deionized water and then dried at 70 °C for 12 h. In order 
to remove the template phase, the mesoporous 
nanoparticles were calcined at 550 °C for 5 h in an 
oxidizing atmosphere.
Synthesis of tert-butyl (3,4-
dihydroxyphenethyl)carbamate (2)37. Dopamine 
hydrochloride (1, 1.00 g, 6.53 mmol) was suspended in 13 
mL of chloroform and then, sodium bicarbonate (0.55 g, 
6.53 mmol) in 9 mL of H2O, NaCl (1.31 g, 22 mmol) and di-
tert-butyl dicarbonate (1.49 g, 6.83 mmol) were 
successively added. The mixture was heated at 62 °C for 3 
h. Afterwards, the organic phase was washed with H2O (40
mL), brine (40 mL), dried over MgSO4, and filtered. Finally, 
the filtrate was concentrated by rotary evaporation and 
the residue was purified by silica gel column 
chromatography using ethyl acetate-hexane as eluent (1:1 
v/v) to obtain the product 2 as a pale pink solid (921 mg, 
3.64 mmol, 56 % yield). (Scheme 2a). 
Synthesis of 4-(2-((tert-
butoxycarbonyl)amino)ethyl)-1,2-phenylene bis((3-
(triethoxysilyl)propyl)carbamate) (3): In a reaction 
vessel purged with Argon, a solution of 2 (0.3 g, 1.18 
mmol) in 15 mL of anhydrous CH3CN was prepared, and 
then (3-isocyanatopropyl)-triethoxysilane (0.6 mL, 2.36 
mmol) was added. The mixture was stirred at room 
temperature for 4 h. Finally, the solvent was removed 
under reduced pressure to obtain product 3 as a pale 
yellow solid (882.6 mg, 1.18 mmol). 1H-NMR (400 MHz, 
CDCl3) δ 7.09 (d, J=8.2 Hz, 1H), 6.99 (d, J=7.3 Hz, 2H), 5.47 
(s, 2H), 4.58 (s, 1H), 3.83 (qdd, J1=7.0, J2=5.0, J3=2.0 Hz, 
15H), 3.36 (d, J=5.7 Hz, 2H), 2.77 (t, J=6.7, 2H), 1.43 (s, 
11H), 1.23 (m, 25H) ppm. 13C-NMR (101 MHz, CDCl3) δ 
157.05, 154.67, 152.89, 141.79, 140.38, 136.03, 125.16, 
122.5, 77.99, 57.25, 42.47, 41.75, 40.27, 34.31, 27.18, 
22.39, 21.94, 17.07, 6.41 ppm. (Figure S1-S2)
Synthesis of S1-Boc. In a typical synthesis, a mixture 
of calcined mesoporous silica nanoparticles (100 mg) and 
rhodamine B (38.3 mg, 0.08 mmol) were suspended in 5 
mL of anhydrous CH3CN and purged with Argon. The 
suspension was stirred at room temperature for 24 h in 
order to load the mesopores. Then, compound 3 (191.5 
mg, 0.26 mmol) was added and the final suspension was 
stirred at room temperature for 5.5 h. Finally, the resulting 
pink solid was filtered and then dried under vacuum 
overnight, giving rise to S1-Boc (195 mg).
Synthesis of S1. Solid S1-Boc (10 mg) was suspended 
in 2 mL of anhydrous CH2Cl2 and purged with Argon. The 
suspension was then cooled to 0 °C and TFA (0.1 mL, 1.31 
mmol) was added for N-Boc deprotection. The mixture was 
stirred at room temperature for 10 minutes and the solid 
was isolated by centrifugation, washed with CH2Cl2 (2 × 8 
mL) and dried overnight at 37 °C. 
Synthesis of S2. Solid S1 (1 mg) was suspended in 
TRIS HCl buffer (300 µL, 20 mM of TRIS and MgCl2·6H2O, 
pH 8.0) and then, the recombinant human transporter 
dopamine protein (150 µL, 0.017 µg/µL) was added. The 
mixture was stirred in a thermo-shaker at 4 °C overnight. 
Then, the suspension was centrifuged at 12,000 rpm for 5 
min. S2 was then washed with TRIS HCl buffer (300 µL) to 
eliminate the non-encapsulated dye and the unattached 
protein.
Release experiments of solid S1 in the presence of 
MDPV. To check the crucial role played by transporter 
dopamine protein (DAT), absent in S1 but present in S2, 1 
mg of solid S1 was suspended in 800 µL of TRIS HCl buffer 

















































































After that, 9 µL of a 20 mM solution of MDPV in TRIS HCl 
buffer were added to one of the aliquots (final 
concentration of 860 µM), and simultaneously, 9 µL of TRIS 
HCl buffer were added to the blank aliquot. Both 
suspensions were stirred at 25 °C and, after certain time, 
aliquots were centrifuged (12,000 rpm for 5 min) and the 
fluorescence of the rhodamine B released in the 
supernatant (λexc = 565 nm, λem = 572 nm) was measured. 
Once measured, the 150 µL were returned to the initial 
suspension (Figure S9). 
Release experiments of solid S2 in the presence of 
MDPV. The same procedure described in the section above 
was carried out with S2 (Figure 1).
Selectivity studies with S2 in TRIS buffer. 1 mg of S2 
was suspended in 1.4 mL of TRIS HCl Buffer (20 mM of 
TRIS and MgCl2·6H2O, pH 8.0) and this volume was 
separated into seven aliquots of 200 µL. Besides, several 
solutions in TRIS HCl buffer of different drugs (MDMA, 
morphine, heroin, cocaine, MDPV, and dopamine) at a 
concentration of 1 mM were prepared. Then, 9 µL of each 
drug solution were added to the aliquots of S2, to reach a 
final concentration of 43 µM. Simultaneously, 9 µl of TRIS 
HCl buffer were added to the blank. The suspensions were 
stirred at 25 °C for 2 minutes. After that, the aliquots were 
centrifuged, and the fluorescence of the rhodamine B 
released in the supernatant was measured (Figure 2).
Determination of detection limit of S2 for MDPV. 1 
mg of S2 was suspended in 2.4 mL of TRIS HCl buffer (20 
mM of TRIS and MgCl2·6H2O, pH 8.0) and then divided into 
twelve aliquots of 200 µL. Then different concentrations of 
MDPV were added to the aliquots. The suspensions were 
stirred at 25 °C for 2 min and then centrifuged (12,000 
rpm for 5 min) and the fluorescence of the rhodamine B 
released in the supernatant (λexc = 565 nm, λem = 572 nm) 
was measured (Figure S10).
Determination of detection limit of S2 with MDPV 
in saliva. 1 mg of S2 was suspended in 2.4 mL of 30 % 
saliva and divided into twelve aliquots of 200 µL each one. 
The experimental procedure followed was the same as 
described above (Figure S14).
Determination of detection limit of S2 with MDPV 
in blood plasma. 1 mg of S2 was suspended in 2.4 mL of 
30 % diluted blood plasma extracted and divided into 
twelve aliquots of 200 µL. The experimental procedure is 
the same as described above (Figure S15).
Detection of MDPV in spiked saliva and plasma 
blood samples. 0.1 mg of solid S2 were added to 200 µL of 
30 % saliva or plasma sample spike with MDPV. All 
suspensions were stirred at 25 °C for 2 minutes. The 
aliquots were centrifuged (12,000 rpm for 5 min) and the 
fluorescence of the rhodamine B released in the 
supernatant (150 µL) was measured (Figure S11-S13). 
RESULTS AND DISCUSSION
Design, synthesis and characterization of the 
nanodevice. For the preparation of the sensing 
nanoparticles, MSNs was first synthesized by base-
catalysed sol–gel condensation of tetraethylorthosilicate 
(TEOS) in the presence of sodium hydroxide and 
hexadecyltrimethylammonium bromide (CTABr) as 
micellar template, following previously reported 
procedures.38,39 The as-made MSNs were calcined at 550 °C 
to obtain the starting nanoparticles. In a second step, the 
pores of the MSNs were loaded with rhodamine B by 
stirring a suspension of nanoparticles in a concentrated 
acetonitrile solution of the fluorophore (S0). Furthermore, 
dopamine derivative 3 was anchored onto the external 
surface of the loaded nanoparticles yielding the solid S1-
Boc. Synthesis of 3 was carried out by protecting the 
amino group of dopamine with di-tert-butyl dicarbonate 
following with reaction with (3-
isocyanatopropyl)triethoxysilane. The Boc protecting 
groups from S1-Boc were removed by using trifluoroacetic 
acid (TFA), giving rise to solid S1 (Scheme 2b). The final 
sensing nanodevice (S2) was obtained after stirring a 
suspension of S1 in TRIS HCl buffer at pH 8.0 and the DAT 
protein overnight.
Scheme 2. (a) Synthesis of dopamine derivative 3. (b) 
Synthetic route for the preparation of solid S2.
All the prepared solids were characterized by using 
standard techniques such as powder X-ray diffraction 
(PXRD), transmission electron microscopy (TEM), N2 
adsorption–desorption isotherms, elemental and 
thermogravimetric analyses, dynamic light scattering 
(DLS) and FTIR (Figures S3-S8). In particular, the PXRD 
pattern of the MSNs as synthesized (Figure S3, curve a) 
shows four low-angle reflections typical of a hexagonal 
array, indexed as (1 0 0), (1 1 0), (2 0 0), and (2 1 0) Bragg 
peaks. Besides a cell parameter a0 of 39.75 Å (distance 
between planes d100 = 34 Å) was determined. A significant 
displacement of 6-8 Å of the (1 0 0) peak in the PXRD 
pattern of the MCM-41 calcined nanoparticles is evident in 
curve b (Figure S3), related to the condensation of silanol 
groups in the calcination step. In S1, a broadening of the (1 
1 0) and (2 0 0) reflections is observed, related to a loss of 
contrast due to filling of the pore with rhodamine B. The 
presence of the mesoporous structure in the final 
functionalized solids was also confirmed by TEM analyses, 
in which the typical hexagonal porosity of a MCM-41-like 
matrix was clearly visualized (Figure S4). The figure also 
shows that the materials are spherical particles with an 





























































average diameter of 100 ± 4 nm (for S2, n = 100 particles). 
The N2 adsorption–desorption isotherms of the calcined 
nanoparticles show a IV type isotherm, typical of 
mesoporous materials (Figure S5). The curve increment at 
P/P0 value (0.2–0.4) is ascribed to the condensation of 
nitrogen by capillarity inside the mesopores. A pore 
diameter of 2.54 nm and a total pore volume of 0.90 cm3 
g−1 were calculated by using the BJH model on the 
adsorption branch of the isotherm. The application of the 
Brunauer-Emmett-Teller (BET) model resulted in a value 
for the total specific surface of 1129 m2 g−1. The N2 
adsorption–desorption isotherm of S1-Boc (Figure S5) is 
typical of mesoporous systems with partially filled 
mesopores. A decrease in the pore volume (0.20 cm3 g−1) 
and surface area (318.48 m2 g−1) was observed. From 
thermogravimetric (Figure S6), elemental analysis and 
delivery studies, contents of 0.3 and 0.19 mmol of 
rhodamine B and 3, respectively per gram of S1-Boc solid 
were calculated. Moreover, contents of 0.07 and 0.16 mmol 
of rhodamine B and 3, respectively per gram of S1 solid 
were determined. Meanwhile, the zeta potential of -29.5 
mV, in the starting MSNs, changed to 22.4 mV for S1-Boc, 
due to attachment of the dopamine derivative, 3. Besides, 
solid S1 presents a potential z value of 29.1 mV because of 
deprotection of amino group, whereas a value of -38.0 mV 
was found for solid S2 on account of the DAT attachment. 
Additionally, the hydrodynamic diameter of the starting 
MSNs was 159 ± 1 nm. S1-Boc presented a hydrodynamic 
diameter of 238 ± 9 nm, which changed to197 ± 2 nm for 
S1 (Figure S7). This decrease in size is in agreement with 
the removal of the protective Boc groups from S1-Boc to 
give S1. Finally, the hydrodynamic diameter for S2 
increased to 501 ± 13 nm due to the attachment of the DAT 
protein. FTIR spectrum of functionalized solid S1 showed 
the typical absorption bands at ca. 1100 and 3400 cm-1 
related to the bond stretching vibrations of Si-O-Si and of 
O-H groups respectively. In addition, the spectrum showed 
the stretching N-H vibrations of amine groups at 3300 cm-
1, which were not present in FTIR spectrum of solid S1-Boc 
(Figure S8). S2 showed absorption bands at ca. 3300, 1760 
and 1500 cm-1 related to the vibrations of N-H, C=O and 
NH3+ respectively.
Figure 1. Kinetics of dye release from solid S2 in TRIS HCl 
Buffer at pH 8.0 in absence (black line) and in presence (red 
line) of MDPV (860 µM). Error bars are expressed as 3σ for 
three independent experiments.
Controlled delivery studies. To assess the feasibility of 
the proposed sensing paradigm, controlled release 
experiments from S2 in the presence of MDPV were 
carried out. For this purpose, S2 was suspended in TRIS 
HCl buffer at pH 8.0 and this volume was divided into two 
aliquots. Then, a solution of MDPV in TRIS HCl buffer were 
added to one of the aliquots (MDPV final concentration of 
860 µM), and simultaneously, TRIS buffer was added to the 
blank aliquot. Both suspensions were stirred at 25 °C and, 
after predefined times, aliquots were taken and 
centrifuged to eliminate the solid and the fluorescence of 
the rhodamine B released in the supernatant (λexc = 565 
nm, λem = 572 nm) was measured. The obtained release 
profiles are shown in Figure 1. As can be seen, in the 
absence of MDPV a low cargo delivery (ca. 7 % of the total 
rhodamine B released after 20 min) was observed, 
indicating that S2 was effectively capped by the interaction 
of the grafted dopamine derivative with DAT. However, in 
the presence of MDPV, a remarkable enhancement in the 
fluorescence emission at 572 nm was detected, as a 
consequence of the selective coordination of the drug with 
DAT, which resulted in DAT displacement from the solid, 
pore opening and rhodamine B release. These results are 
consistent with the fact that MDPV shows high affinity for 
DAT in the low nanomolar range (10 ± 2 nM) compared to 
the low affinity presented for other transporters such as 
serotonin (2.86 ± 0.1 µM)40 Likewise, MDPV produces a 
highly potent DAT inhibition with an IC50 value of 4.1 ± 0.5 
nM in contrast to the weak effect produced by serotonin 
and norepinephrine transporters (IC50 = 3349 ± 305 and 
26 ± 8 nM, respectively).41, 42 Besides, in order to 
demonstrate that DAT plays a key role in the gating 
mechanism, we measured the delivery profiles of the 
uncapped solid S1 in absence and presence of MDPV 
(Figure S9). In both cases, a marked rhodamine B release 
was observed.
Scheme 3. Chemical structure of the drugs used as 
interferents for selectivity studies. 
To study the sensitivity of S2 towards MDPV, the 
fluorogenic response of TRIS HCl buffer suspensions of the 
nanodevices upon addition of increasing amounts of the 
drug was studied (Figure S10). The results showed an 
increase in the rhodamine B emission at 572 nm after 2 
min upon addition of increasing concentrations of MDPV. 





























































From the titration profile, a detection limit for MDPV of 5.2 
µM was determined from the intersection between two 
linear sections of the calibration curve. The detection limit 
achieved enables a commonly occurring dose of MDPV (5 
mg) to be detected in volumes as high as 3.5 L. 
In a further step, the fluorogenic response of S2 was 
also evaluated in the presence of other common drugs 
such as cocaine, heroin, dopamine, MDMA, and morphine 
(Scheme 3). Figure 2 shows the emission of the released 
rhodamine B at 572 nm after 2 min from suspensions of S2 
in TRIS HCl buffer at pH 8.0 upon addition of the selected 
drugs (1 mM). As can be seen, a remarkable enhancement 
in the fluorescence intensity is only produced by MDPV, 
while other drugs were unable to induce such a 
remarkable change. The observed selectivity of S2 toward 
MDPV is in agreement with its higher IC50 inhibition value 
(4.1 ± 0.5 nM) to DAT compared to other tested drugs such 
as cocaine or MDMA (IC50 = 211 ± 19 and 93 ± 17, 
respectively).41 Therefore, none of the other interferents 
tested presented remarkable affinities with DAT and, as a 
consequence, negligible rhodamine B release was observed 
in these cases. This suggested that S2 could be used for the 
selective detection of MDPV.
Figure 2. Effect of the indicated drugs (1 mM) on the relative 
rhodamine B release from solid S2 in TRIS HCl buffer at pH 
8.0 20 min after addition. Error bars are expressed as 3σ for 
three independent experiments (***p<0.0003).
Validation studies in realistic samples. In order to 
evaluate the applicability of the nanosensor in realistic 
competitive environments, we tested the ability of S2 to 
detect MDPV in real samples of both saliva and blood 
plasma. In this way, we prepared a solution of 30 % saliva 
and then the release of rhodamine B from S2 nanoparticles 
in the presence (860 µM) and absence of the drug was 
measured. The results obtained (Figure S11) showed that 
while in absence of MDPV a moderate dye release was 
found (15 % of the total dye released after 30 min), in the 
presence of the illicit drug a marked rhodamine B release 
was produced (98 % after ca. 30 min). Moreover, the 
sensitivity of S2 in saliva was measured, showing a 
detection limit for MDPV of 6.9 µM (Figure S14). 
In addition, we tested the ability of S2 to detect MDPV 
in a solution of 30 % blood plasma previously spiked with 
MDPV (860 µM) (Figure S12). As shown in the Figure S13 
rhodamine B release was observed when the drug was 
present in blood plasma solution (98 % of dye released 
after 20 min), while the nanoparticles remained “closed” 
when no MDPV was present, and the fluorescence 
emission was significantly lower (20 % after ca. 20 min). 
The detection limit of MDPV in blood plasma for S2 was as 
low as 12.1 µM (Figure S15). Detection limit values 
obtained in saliva and in plasma are slightly higher than 
that measured in TRIS HCl solution (vide ante), most 
probably due to the presence of a higher competitive 
environment.
Finally, the nanosensor was tested for MDPV detection 
in saliva and blood plasma samples (200 µL) spiked with 
17.9 and 215 µM of the cannibal drug, respectively. 0.1 mg 
of solid S2 was added to the corresponding solution and 
the samples were shaken for 2 minutes at room 
temperature. From the interpolation in calibration curves 
of the rhodamine released from S2 in these media, 
concentrations of MDPV of 17.6 and 200 μM were 
determined for the saliva and plasma samples, respectively 
(recovery values of 98 % and 93 %).
CONCLUSIONS
In summary, we report herein the design, synthesis, 
characterization and sensing behaviour of a probe for the 
fast and highly selective detection of the cathinone MDPV 
(cannibal drug). The nanosensor consists of MSNs loaded 
with rhodamine B and capped with DAT. In the presence of 
the MDPV drug, DAT is detached from the nanosensor, 
inducing cargo release. This behaviour is observed in the 
presence of MDPV but not with other common drugs like 
cocaine, morphine, heroin, heroin or MDMA. The probe 
shows a high sensitivity in TRIS HCl buffer (detection limit 
of 5.2 µM) and in realistic competitive media like saliva 
(6.9 µM) and blood plasma (12.1 µM). Finally, the probe is 
able to detect MDPV in spiked saliva and serum samples. 
Considering the sensitivity and selectivity of S2 and its 
easy synthesis and handling, this material could be used as 
a reliable system for the accurate ‘in situ’ and ‘at site’ 
MDPV identification.
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SYNOPSIS TOC. A novel bio-inspired nanodevice for the selective and sensitive fluorogenic detection of 3,4-
methylenedioxypyrovalerone (MDPV), usually known as Cannibal drug, is presented. The developed nanodevice is 
based on MCM-41 type mesoporous silica nanoparticles (MSNs). These are loaded with rhodamine B (as a fluorescent 
reporter) and functionalized on their external surface with a dopamine derivative (which specifically interacts with 
the recombinant human dopamine transporter, DAT) capping the pores. In the presence of MDPV, DAT detaches from 
the external surface of the MSNs consequently causing rhodamine B release and allowing drug detection. Thanks to 
its excellent features, this nanosensor might be useful as a highly selective and sensitive fluorometric probe for the 
detection of MDPV drug both in saliva and blood plasma samples.
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